Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (790)	1/21/1998 8:24:00 PM
From: Harold Lehman	Read Replies (1) \| Respond to of 1501

When you say no response, what is the response (physiological, immunological or biochemical) that you are referring to? I'm sorry to harp on this, but it's important(to me) to know the reference points for comparison. I would like to know if the data really shows a 90% or better inhibition, in sheep, to allergen-induced bronchoconstriction with the Biogen/Merck product in development, or if that 90% that you are referring to is about some other response altogether, which might be nonclinical. Thank you for your efforts. HL